As previously reported, Cantor Fitzgerald initiated coverage of InflaRx (IFRX) with an Overweight rating and $10 price target Upcoming Phase 3 interim data due in May for the company’s lead asset vilobelimab in pyoderma gangrenosum is a “potentially major, unappreciated catalyst,” the analyst tells investors. The risk/reward into this blinded interim analysis has a “very large positive skew,” the analyst argues.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx initiated with an Overweight at Cantor Fitzgerald
- InflaRx Approves Key Resolutions at Annual Shareholder Meeting
- InflaRx N.V. Announces 2025 Annual General Meeting Agenda
- InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
- InflaRx price target raised to $10 from $7 at Guggenheim